Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. Related Stories Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease The Key Role of iPSC-Derived Microglia in Research and Drug Discovery The acquisition extends Axol's portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services.
Phenocell's offering includes market-leading human iPSC-derived sebocytes and retinal pigment epithelium (RPE) and photoreceptor cells. Additionally, the company provides custom, skin and dry age-related macular degeneration (AMD) services to support drug discovery companies. Axol has previously operated in three areas of drug research and discovery: neuroscience, pain and touch, and cardiovascular drug discovery.
This acquisition enables us to extend our product portfolio into ophthalmology and dermatology and offer iPSC-based skin and vision loss models. We are delighted to welcome Phenocell to the Axol Bioscience family and look forward to building an even wider range of advanced in vitro models of human disease, co.
